129 related articles for article (PubMed ID: 22076450)
1. Sporadic CNS hemangioblastomatosis, response to sunitinib and secondary polycythemia.
Reyes-Botero G; Gállego Pérez-Larraya J; Sanson M
J Neurooncol; 2012 Apr; 107(2):439-40. PubMed ID: 22076450
[No Abstract] [Full Text] [Related]
2. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
Alexandrescu DT; McClure R; Farzanmehr H; Dasanu CA
J Clin Oncol; 2008 Aug; 26(24):4047-8. PubMed ID: 18711201
[No Abstract] [Full Text] [Related]
3. Sunitinib-induced hemoglobin changes are related to the dosing schedule.
van der Veldt AA; Boven E; Vroling L; Broxterman HJ; van den Eertwegh AJ; Haanen JG
J Clin Oncol; 2009 Mar; 27(8):1339-40; author reply 1340-2. PubMed ID: 19188672
[No Abstract] [Full Text] [Related]
4. Reversible posterior leukoencephalopathy syndrome induced by sunitinib.
Martín G; Bellido L; Cruz JJ
J Clin Oncol; 2007 Aug; 25(23):3559. PubMed ID: 17687168
[No Abstract] [Full Text] [Related]
5. "Pseudocavitation" in thymic carcinoma during treatment with sunitinib.
Tiseo M; Rajan A; Thomas A; Giaccone G
J Thorac Oncol; 2013 Apr; 8(4):511-2. PubMed ID: 23486269
[No Abstract] [Full Text] [Related]
6. Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.
Jonasch E; McCutcheon IE; Waguespack SG; Wen S; Davis DW; Smith LA; Tannir NM; Gombos DS; Fuller GN; Matin SF
Ann Oncol; 2011 Dec; 22(12):2661-2666. PubMed ID: 22105611
[TBL] [Abstract][Full Text] [Related]
7. Erosive nappy erythema following sunitinib intake.
Kharmoum S; Errihani H
Pan Afr Med J; 2013; 14():46. PubMed ID: 23560129
[No Abstract] [Full Text] [Related]
8. Risks associated with sunitinib use and monitoring to improve patient outcomes.
Choi BS
Korean J Intern Med; 2014 Jan; 29(1):23-6. PubMed ID: 24574829
[No Abstract] [Full Text] [Related]
9. Sunitinib-induced thyrotoxicosis.
Piñar D; Boix E; Meana JA; Herrero J
J Endocrinol Invest; 2009 Dec; 32(11):941-2. PubMed ID: 19636224
[No Abstract] [Full Text] [Related]
10. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer.
Kalantari HR
Br J Cancer; 2009 Oct; 101(7):1222-3; author reply 1224. PubMed ID: 19755985
[No Abstract] [Full Text] [Related]
11. Myelosuppression by sunitinib is flt-3 genotype dependent.
van Erp NP; Mathijssen RH; van der Veldt AA; Haanen JB; Reyners AK; Eechoute K; Boven E; Wessels JA; Guchelaar HJ; Gelderblom H
Br J Cancer; 2010 Aug; 103(5):757-8. PubMed ID: 20683446
[No Abstract] [Full Text] [Related]
12. Sunitinib-induced thrombotic microangiopathy.
Noronha V; Punatar S; Joshi A; Desphande RV; Prabhash K
J Cancer Res Ther; 2016; 12(1):6-11. PubMed ID: 27072203
[TBL] [Abstract][Full Text] [Related]
13. Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma.
Flaig TW; Kim FJ; La Rosa FG; Breaker K; Schoen J; Russ PD
Invest New Drugs; 2009 Feb; 27(1):83-7. PubMed ID: 18563296
[No Abstract] [Full Text] [Related]
14. Neurosensory retinal detachment due to sunitinib treatment.
Wegner A; Khoramnia R
Eye (Lond); 2011 Nov; 25(11):1517-8. PubMed ID: 21852804
[No Abstract] [Full Text] [Related]
15. Cardiac toxicity of sunitinib.
Joensuu H
Lancet; 2007 Dec; 370(9604):1978-80. PubMed ID: 18083385
[No Abstract] [Full Text] [Related]
16. Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy.
van der Veldt AA; van den Eertwegh AJ; Hoekman K; Barkhof F; Boven E
Ann Oncol; 2007 Oct; 18(10):1747-50. PubMed ID: 17890217
[No Abstract] [Full Text] [Related]
17. Recall pneumonitis during systemic treatment with sunitinib.
Seidel C; Janssen S; Karstens JH; Welte T; Morgan M; Ganser A; Grünwald V
Ann Oncol; 2010 Oct; 21(10):2119-2120. PubMed ID: 20720089
[No Abstract] [Full Text] [Related]
18. Summaries for patients. Underactive thyroid function after treatment with sunitinib for gastrointestinal cancer.
Ann Intern Med; 2006 Nov; 145(9):I44. PubMed ID: 17088575
[No Abstract] [Full Text] [Related]
19. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome.
Kapiteijn E; Brand A; Kroep J; Gelderblom H
Ann Oncol; 2007 Oct; 18(10):1745-7. PubMed ID: 17890216
[No Abstract] [Full Text] [Related]
20. [Sunitinib-induced pyoderma gangrenosum].
Schmutz JL; Trechot P
Ann Dermatol Venereol; 2013 Dec; 140(12):841-2. PubMed ID: 24315238
[No Abstract] [Full Text] [Related]
[Next] [New Search]
